Published in Lab Law Weekly, March 26th, 2010
Under the terms of the agreement, BioInvent will apply its state-of-the art antibody discovery technology to generate and develop monoclonal antibody candidates. The collaboration will initially focus on the development of antibodies in the field of inflammation. BioInvent and HGS will each have the right to participate in development and global commercialization of each antibody candidate, and will share...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly